Complement and Immunotherapy of Breast Cancer
Annual summary 15 Sep 2007-14 Sep 2008
MEDICAL UNIV OF SOUTH CAROLINA CHARLESTON
Pagination or Media Count:
In general, monoclonal antibody immunotherapy for cancer has fallen short of clinical expectations. This is due, at least in part, to the over expression of membrane-bound complement inhibitors on the tumor cell surface. The authors proposed to prepare and investigate the effects of two novel recombinant proteins aimed at modulating complement to increase the immune response to breast tumors. During year two it was proposed to finish construction, expression, and purification of CR2Fc characterize the recombinant protein in vitro and begin in vivo studies. Construction and purification of CR2Fc has been accomplished. The purification of the protein was optimized and stocks of protein have been produced for these studies. The protein has been characterized in vitro and shown to bind C3 deposited on tumor cells. Technical difficulties were encountered in vitro when looking at increased C3 deposition and tumor cell lysis but are currently being resolved. The authors will finish in vitro studies and proceed with in vivo studies to determine the effect CR2Fc has on the immune response and whether it is protective against breast tumors.
- Genetic Engineering and Molecular Biology
- Anatomy and Physiology
- Medicine and Medical Research